The other is moderate to severe obstructive sleep apnea in people with obesity. Mounjaro contains the same molecule and is approved for type 2 diabetes.1
What it is
Tirzepatide acts on two receptors, those of the gut hormones GIP and GLP-1, which is why the label calls it a GIP receptor and GLP-1 receptor agonist.1 Wegovy, its closest rival for weight, contains semaglutide and acts on the GLP-1 receptor only. The label gives 2022 as the first U.S. approval of tirzepatide. The half-life is about 5 days.1
Zepbound comes in single-dose pens, single-dose vials, multi-dose vials and a KwikPen that holds four weekly doses.1 It is injected under the skin of the abdomen or thigh, or by another person into the back of the upper arm, once a week, at any time of day, with or without meals. The label says not to use it together with another tirzepatide product or with any GLP-1 receptor agonist.1
Who the label approves it for
- Weight. Adults with obesity, or adults with overweight and at least one weight-related condition, to reduce excess body weight and maintain the reduction long term.
- Sleep apnea. Adults with obesity and moderate to severe obstructive sleep apnea.
Both uses are listed as additions to a reduced-calorie diet and increased physical activity. Unlike the Wegovy injection, Zepbound is not approved for teenagers: the label says its safety and effectiveness in children have not been established.1
How the dose climbs
Treatment starts at 2.5 mg once a week for 4 weeks, then rises in steps of 2.5 mg, each after at least 4 weeks on the current dose, until the maintenance dose is reached. For weight that is 5 mg, 10 mg or 15 mg a week; for sleep apnea, 10 mg or 15 mg. The label asks the prescriber to weigh response and tolerability when choosing it.1 Our page on the Zepbound dosing schedule turns the steps into dates.
What it did in trials
The label's 72-week trial enrolled adults without diabetes, who started at an average of 102.9 to 105.8 kg. Weight fell by 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. A loss of at least 20% of starting weight was reached by 30.0%, 50.1% and 56.7% on the three doses, against 3.1% on placebo.1 In adults with type 2 diabetes the losses were smaller: 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo.1
Two 52-week trials tested it in 469 adults with obesity and moderate to severe sleep apnea, one in people who could not or would not use a breathing machine at night and one in people who did. The apnea-hypopnea index, the number of breathing pauses and shallow breaths an hour, started at about 46 to 53. It fell by 25.3 and 29.3 events an hour on Zepbound, against 5.3 and 5.5 on placebo.1
Side effects and warnings
In the weight trials, nausea was reported by 25%, 29% and 28% on 5, 10 and 15 mg, against 8% on placebo. Diarrhea was reported by 19% to 23% against 8%, vomiting by 8% to 13% against 2%, and constipation by 11% to 17% against 5%.1 Our Zepbound side effects timeline shows when they tend to start and fade.
Zepbound carries the boxed warning about thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1 As with Mounjaro, people on birth control pills are advised to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.1
Zepbound in eight lines
| Fact | Zepbound |
|---|---|
| Active ingredient | Tirzepatide |
| Maker | Eli Lilly |
| Approved for | Weight, obstructive sleep apnea |
| Receptors | GIP and GLP-1 |
| How often | Once a week, under the skin |
| Doses | 2.5 mg to start; 5, 10 or 15 mg to stay on |
| Half-life | About 5 days |
| Children and teens | Not established |
ZEPBOUND prescribing information, revised August 2026.1
Related terms
Mounjaro is the same tirzepatide for type 2 diabetes, and Wegovy is the semaglutide brand for the same weight use. Our pages compare Mounjaro and Zepbound and set out what Zepbound costs, including the self-pay vials.
Sources
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 4, 5, 6.1, 8.3, 12 and 14. accessdata.fda.gov
Related analyses
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
Zepbound cost: what you pay with insurance, without it, and over a year
Zepbound side effects timeline: when they start, how long they last, when they ease
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Log each Zepbound dose and your weight, and see the trend on one chart.
Open Dose Insider